ACP3 and neoplasm: Early generations of cancer vaccines, which primarily targeted tumor-associated antigens (TAAs) such as MUC1, HER2, or prostate acid phosphatase (PAP), often failed to achieve durable clinical benefit due to immune tolerance mechanisms, antigen heterogeneity, and the low intrinsic immunogenicity of self-derived proteins.